Eubacterial tmRNA sequences and uses thereof
AssigneeUniversity of Utah Research Foundation
InventorBrice Felden
Life of this patent
Estimating the term…
Abstract
The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.
Claims5
An isolated nucleotide sequence comprising a tmDNA sequence selected from the group of tmDNA sequences set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:3 1, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65 and SEQ ID NO:66, a corresponding RNA of said tmDNA sequence, said RNA comprising the tmRNA sequence set forth in SEQ ID NOs:67-175 or a complement of said tmDNA sequence.
A method for diagnosing a bacterial infectious agent comprising determining the presence of a bacterial tmDNA selected from the group of tmDNA sequences set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65 and SEQ ID NO:66, a corresponding RNA of said tmDNA sequence, said RNA comprising the tmRNA sequence set forth in SEQ ID NOs:67-175 or a complement of said tmDNA sequence.
A method for screening compounds to identify a drug candidate for treating a bacterial infection comprising testing a compound for its ability to interupt a tmRNA structural domain selected from the group consisting of a H2 helix, a H5 helix, a PK1 pseudoknot, a PK2 pseudoknot, a PK3 pseudoknot or a PK4 pseudoknot.
A method for treating a bacterial infection comprising administering to an individual in need thereof a therapeutically effective amount of (a) an antisense oligonucleotide to the coding sequence of a tmRNA or (b) a drug which interupts a tmRNA structural domain selected from the group consisting of a H2 helix, a H5 helix, a PK1 pseudoknot, a PK2 pseudoknot, a PK3 pseudoknot or a PK4 pseudoknot.
Dependencies are inferred from the claim text.